Abstract
The definitive treatment of early stage prostate cancer with radiation therapy has progressed dramatically over the past two decades primarily due to the development and implementation of intensity-modulated radiation therapy (IMRT) techniques and better definition of the role of androgen deprivation therapy (ADT). IMRT has permitted the escalation of radiotherapy dose to the target tissues, namely, the prostate and proximal seminal vesicles, in an effort to improve tumor cell killing and local tumor control, while also reducing dose to nearby organs at risk (OARs) including the bladder, rectum, bowel, femoral heads, and penile bulb. Advances in image-guided radiotherapy (IGRT) have improved the accuracy of the delivery of IMRT, reduced PTV margins, and consequently decreased acute and long-term side effects. This chapter will review the clinical evidence for the use of IMRT for early stage, clinically localized (T1–2N0M0) prostate cancer and will outline the processes involved in designing and implementing a safe and effective IMRT treatment plan.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29
Eccles BK et al (2013) SABRE 1 (Surgery Against Brachytherapy – a Randomised Evaluation): feasibility randomised controlled trial (RCT) of brachytherapy vs radical prostatectomy in low-intermediate risk clinically localised prostate cancer. BJU Int 112(3):330–337
Kuban DA et al (2003) Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57(4):915–928
Pilepich MV et al (1987) Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate–analysis of RTOG study 75–06. Int J Radiat Oncol Biol Phys 13(3):351–357
Hanks GE, Martz KL, Diamond JJ (1988) The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 15(6):1299–1305
Valicenti R et al (2000) Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 18(14):2740–2746
Zelefsky MJ et al (2008) Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 179(4):1368–1373; discussion 1373
Leibel SA et al (1994) The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol 21(5):580–597
Ten Haken RK et al (1989) Boost treatment of the prostate using shaped, fixed fields. Int J Radiat Oncol Biol Phys 16(1):193–200
Eade TN et al (2007) What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 68(3):682–689
Kuban DA et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67–74
Zietman AL et al (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. J Am Med Assoc 294(10):1233–1239
Peeters ST et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24(13):1990–1996
Dearnaley DP et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8(6):475–487
Beckendorf V et al (2011) 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 80(4):1056–1063
Viani GA, Stefano EJ, Afonso SL (2009) Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 74(5):1405–1418
Ling CC et al (1996) Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys 35(4):721–730
Marchal C et al (2004) Preliminary results of the assessment of intensity modulated radiotherapy (IMRT) for prostatic and head and neck tumors (STIC 2001). Cancer Radiother 8(Suppl 1):S121–S127
Nutting CM et al (2000) Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 48(3):649–656
Vlachaki MT et al (2005) IMRT versus conventional 3DCRT on prostate and normal tissue dosimetry using an endorectal balloon for prostate immobilization. Med Dosim 30(2):69–75
Ashman JB et al (2005) Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 63(3):765–771
Kao J et al (2004) Sparing of the penile bulb and proximal penile structures with intensity-modulated radiation therapy for prostate cancer. Br J Radiol 77(914):129–136
Ailleres N et al (2004) Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer. Cancer Radiother 8(2):59–69
Wang-Chesebro A et al (2006) Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 66(3):654–662
Perna L et al (2009) Sparing the penile bulb in the radical irradiation of clinically localised prostate carcinoma: a comparison between MRI and CT prostatic apex definition in 3DCRT, Linac-IMRT and Helical Tomotherapy. Radiother Oncol 93(1):57–63
Zelefsky MJ et al (2000) Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55(3):241–249
Zelefsky MJ et al (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166(3):876–881
Al-Mamgani A et al (2009) Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 73(3):685–691
De Meerleer G et al (2004) Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 60(3):777–787
Kry SF et al (2005) The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 62(4):1195–1203
Brenner DJ et al (2000) Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88(2):398–406
Brenner DJ (2006) Induced second cancers after prostate-cancer radiotherapy: no cause for concern? Int J Radiat Oncol Biol Phys 65(3):637–639
Nieder AM, Porter MP, Soloway MS (2008) Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol 180(5):2005–2009; discussion 2009–10
Singh AK et al (2010) Increasing age and treatment modality are predictors for subsequent diagnosis of bladder cancer following prostate cancer diagnosis. Int J Radiat Oncol Biol Phys 78(4):1086–1094
Kendal WS et al (2006) Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer. Int J Radiat Oncol Biol Phys 65(3):661–668
Isebaert S et al (2013) Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology. J Magn Reson Imaging 37(6):1392–1401
Sciarra A et al (2011) Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 59(6):962–977
Hegde JV et al (2013) Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging 37(5):1035–1054
Vargas HA et al (2011) Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 259(3):775–784
Coakley FV et al (2002) Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 223(1):91–97
Mazaheri Y et al (2008) Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging–correlation with pathologic findings. Radiology 246(2):480–488
Hambrock T et al (2011) Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 259(2):453–461
Padhani AR et al (2000) Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 55(2):99–109
Turnbull LW et al (1999) Differentiation of prostatic carcinoma and benign prostatic hyperplasia: correlation between dynamic Gd-DTPA-enhanced MR imaging and histopathology. J Magn Reson Imaging 9(2):311–316
Girouin N et al (2007) Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 17(6):1498–1509
Schmuecking M et al (2009) Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer? Int J Radiat Biol 85(9):814–824
Singh AK et al (2007) Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol 2:36
Fonteyne V et al (2008) Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 72(3):799–807
Ippolito E et al (2012) Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity. Am J Clin Oncol 35(2):158–162
Aluwini S et al (2013) Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol 8:84
Riches SF et al (2014) Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters. Br J Radiol 87(1037):20130813
Murray LJ et al (2014) Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions. Int J Radiat Oncol Biol Phys 89(2):406–415
Bauman G et al (2013) Boosting imaging defined dominant prostatic tumors: a systematic review. Radiother Oncol 107(3):274–281
van Lin EN et al (2006) IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 65(1):291–303
Shinohara K, Roach M 3rd (2008) Technique for implantation of fiducial markers in the prostate. Urology 71(2):196–200
Gauthier I et al (2009) Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment. Int J Radiat Oncol Biol Phys 74(4):1128–1133
Chung PW et al (2004) On-line aSi portal imaging of implanted fiducial markers for the reduction of interfraction error during conformal radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 60(1):329–334
Schallenkamp JM et al (2005) Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. Int J Radiat Oncol Biol Phys 63(3):800–811
Beltran C, Herman MG, Davis BJ (2008) Planning target margin calculations for prostate radiotherapy based on intrafraction and interfraction motion using four localization methods. Int J Radiat Oncol Biol Phys 70(1):289–295
Kupelian PA et al (2005) Intraprostatic fiducials for localization of the prostate gland: monitoring intermarker distances during radiation therapy to test for marker stability. Int J Radiat Oncol Biol Phys 62(5):1291–1296
Poggi MM et al (2003) Marker seed migration in prostate localization. Int J Radiat Oncol Biol Phys 56(5):1248–1251
Gill S et al (2012) Patient-reported complications from fiducial marker implantation for prostate image-guided radiotherapy. Br J Radiol 85(1015):1011–1017
Igdem S et al (2009) Implantation of fiducial markers for image guidance in prostate radiotherapy: patient-reported toxicity. Br J Radiol 82(983):941–945
Alonso-Arrizabalaga S et al (2007) Prostate planning treatment volume margin calculation based on the ExacTrac X-Ray 6D image-guided system: margins for various clinical implementations. Int J Radiat Oncol Biol Phys 69(3):936–943
Nederveen AJ et al (2003) Comparison of megavoltage position verification for prostate irradiation based on bony anatomy and implanted fiducials. Radiother Oncol 68(1):81–88
Langen KM et al (2008) Observations on real-time prostate gland motion using electromagnetic tracking. Int J Radiat Oncol Biol Phys 71(4):1084–1090
Abramowitz M (2012) Noninvasive real-time prostate tracking using a transperineal ultrasound approach. Int J Radiat Oncol Biol Phys 84(3):1
Noel C et al (2009) Prediction of intrafraction prostate motion: accuracy of pre- and post-treatment imaging and intermittent imaging. Int J Radiat Oncol Biol Phys 73(3):692–698
Bittner N et al (2010) Electromagnetic tracking of intrafraction prostate displacement in patients externally immobilized in the prone position. Int J Radiat Oncol Biol Phys 77(2):490–495
Coakley FV, Hricak H (2000) Radiologic anatomy of the prostate gland: a clinical approach. Radiol Clin N Am 38(1):15–30
Zackrisson B, Hugosson J, Aus G (2000) Transrectal ultrasound anatomy of the prostate and seminal vesicles in healthy men. Scand J Urol Nephrol 34(3):175–180
McLaughlin PW et al (2010) Radiographic and anatomic basis for prostate contouring errors and methods to improve prostate contouring accuracy. Int J Radiat Oncol Biol Phys 76(2):369–378
Villeirs GM, De Meerleer GO (2007) Magnetic resonance imaging (MRI) anatomy of the prostate and application of MRI in radiotherapy planning. Eur J Radiol 63(3):361–368
Debois M et al (1999) The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer. Int J Radiat Oncol Biol Phys 45(4):857–865
Milosevic M et al (1998) Magnetic resonance imaging (MRI) for localization of the prostatic apex: comparison to computed tomography (CT) and urethrography. Radiother Oncol 47(3):277–284
Smith WL et al (2007) Prostate volume contouring: a 3D analysis of segmentation using 3DTRUS, CT, and MR. Int J Radiat Oncol Biol Phys 67(4):1238–1247
Roach M 3rd et al (1996) Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 35(5):1011–1018
Rasch C et al (1999) Definition of the prostate in CT and MRI: a multi-observer study. Int J Radiat Oncol Biol Phys 43(1):57–66
van Herk M et al (1998) Automatic registration of pelvic computed tomography data and magnetic resonance scans including a full circle method for quantitative accuracy evaluation. Med Phys 25(10):2054–2067
Gofrit ON et al (2009) The dimensions and symmetry of the seminal vesicles. J Robot Surg 3:29–33
Banner MP, Hassler R (1978) The normal seminal vesiculogram. Radiology 128(2):339–344
Secaf E et al (1991) MR imaging of the seminal vesicles. AJR Am J Roentgenol 156(5):989–994
Villeirs GM et al (2005) Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer. Strahlenther Onkol 181(7):424–430
Wallner KE et al (2002) Penile bulb imaging. Int J Radiat Oncol Biol Phys 53(4):928–933
van der Wielen GJ, Mulhall JP, Incrocci L (2007) Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review. Radiother Oncol 84(2):107–113
Buyyounouski MK et al (2004) The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys 59(5):1383–1391
Brown MW et al (2007) An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma. Prostate Cancer Prostatic Dis 10(2):189–193
Macdonald AG et al (2005) Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: is dose to the penile bulb important? Int J Radiat Oncol Biol Phys 63(1):155–163
Merrick GS et al (2005) Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 62(2):437–447
Roach M et al (2004) Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys 60(5):1351–1356
Poon DM et al (2013) Dosimetric advantages and superior treatment delivery efficiency of RapidArc over conventional intensity-modulated radiotherapy in high-risk prostate cancer involving seminal vesicles and pelvic nodes. Clin Oncol (R Coll Radiol) 25(12):706–712
Kopp RW et al (2011) VMAT vs. 7-field-IMRT: assessing the dosimetric parameters of prostate cancer treatment with a 292-patient sample. Med Dosim 36(4):365–372
Iori M et al (2008) Dose-volume and biological-model based comparison between helical tomotherapy and (inverse-planned) IMAT for prostate tumours. Radiother Oncol 88(1):34–45
Korreman S et al (2010) The European Society of Therapeutic Radiology and Oncology-European Institute of Radiotherapy (ESTRO-EIR) report on 3D CT-based in-room image guidance systems: a practical and technical review and guide. Radiother Oncol 94(2):129–144
Landoni V et al (2006) A study of the effect of setup errors and organ motion on prostate cancer treatment with IMRT. Int J Radiat Oncol Biol Phys 65(2):587–594
Alasti H et al (2001) Portal imaging for evaluation of daily on-line setup errors and off-line organ motion during conformal irradiation of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49(3):869–884
Vigneault E et al (1997) Electronic portal imaging device detection of radioopaque markers for the evaluation of prostate position during megavoltage irradiation: a clinical study. Int J Radiat Oncol Biol Phys 37(1):205–212
Moseley DJ et al (2007) Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 67(3):942–953
Roeske JC et al (1995) Evaluation of changes in the size and location of the prostate, seminal vesicles, bladder, and rectum during a course of external beam radiation therapy. Int J Radiat Oncol Biol Phys 33(5):1321–1329
Zelefsky MJ et al (1999) Quantification and predictors of prostate position variability in 50 patients evaluated with multiple CT scans during conformal radiotherapy. Radiother Oncol 50(2):225–234
Antolak JA et al (1998) Prostate target volume variations during a course of radiotherapy. Int J Radiat Oncol Biol Phys 42(3):661–672
Beard CJ et al (1996) Analysis of prostate and seminal vesicle motion: implications for treatment planning. Int J Radiat Oncol Biol Phys 34(2):451–458
de Crevoisier R et al (2005) Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 62(4):965–973
Heemsbergen WD et al (2007) Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 GY versus 78 Gy. Int J Radiat Oncol Biol Phys 67(5):1418–1424
Kupelian PA et al (2008) Impact of image guidance on outcomes after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70(4):1146–1150
Hanna SA et al (2012) Role of intra- or periprostatic calcifications in image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 82(3):1208–1216
Ryan D et al (2009) Prostate positioning errors associated with two automatic registration based image guidance strategies. J Appl Clin Med Phys 10(4):3071
Bylund KC et al (2008) Analysis of interfraction prostate motion using megavoltage cone beam computed tomography. Int J Radiat Oncol Biol Phys 72(3):949–956
Gayou O, Miften M (2008) Comparison of mega-voltage cone-beam computed tomography prostate localization with online ultrasound and fiducial markers methods. Med Phys 35(2):531–538
Kupelian P et al (2007) Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys 67(4):1088–1098
Scarbrough TJ et al (2006) Comparison of ultrasound and implanted seed marker prostate localization methods: implications for image-guided radiotherapy. Int J Radiat Oncol Biol Phys 65(2):378–387
Boda-Heggemann J et al (2008) Accuracy of ultrasound-based (BAT) prostate-repositioning: a three-dimensional on-line fiducial-based assessment with cone-beam computed tomography. Int J Radiat Oncol Biol Phys 70(4):1247–1255
Pollack A et al (2013) Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31(31):3860–3868
Spratt DE et al (2013) Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 85(3):686–692
Spratt DE et al (2014) Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int 114(3):360–367
Pickett B et al (1999) Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 44(4):921–929
Pucar D et al (2007) Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 69(1):62–69
D’Amico AV et al (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. J Am Med Assoc 299(3):289–295
Jones CU et al (2011) Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365(2):107–118
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Japan
About this chapter
Cite this chapter
Scott, M., Orman, A., Pollack, A. (2015). Early Prostate Cancer (T1–2N0M0). In: Nishimura, Y., Komaki, R. (eds) Intensity-Modulated Radiation Therapy. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55486-8_19
Download citation
DOI: https://doi.org/10.1007/978-4-431-55486-8_19
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-55485-1
Online ISBN: 978-4-431-55486-8
eBook Packages: MedicineMedicine (R0)